JLL Expands Its Global Life Sciences Division
JLL has appointed a seasoned industry veteran to lead its life sciences operations in Canada. The Chicago-based real estate services firm made this strategic hire to strengthen its foothold in a sector that is rapidly gaining momentum. Mark Seliskar, a licensed engineer based in Montreal, joins JLL as its life sciences regional lead for Canada. His appointment signals the firm’s confidence in Canada as a growing hub for pharmaceutical and biotech real estate.
Mark Seliskar: Role and Background
From Sodexo Quebec to JLL Canada
Seliskar brings a rich background to his new role. He previously served as the subject matter expert for pharma and life science operations at Sodexo Quebec, one of the world’s largest food services and facilities management companies. At JLL, he will deliver integrated facilities management solutions for pharmaceutical and life sciences clients with sites across Canada.
Furthermore, Seliskar brings specialized expertise in several critical areas:
- Good Manufacturing Practice (GMP) facilities, which govern quality, purity, and safety in pharmaceutical and medical device production
- Capital project management, covering large-scale infrastructure development
- Validation and compliance remediation, ensuring facilities meet rigorous regulatory standards
Leadership Welcomes the Appointment
Kevin Wayer, JLL’s division president of global life sciences, described the hire as a direct reflection of the firm’s ongoing investment in its Life Sciences brand. He noted that attracting top-tier talent with deep industry knowledge in key markets like Canada demonstrates JLL’s commitment to becoming the trusted partner of choice for pharmaceutical and biotechnology companies worldwide. Seliskar himself expressed excitement about stepping into the role at a pivotal moment for the sector.
Why Canada’s Life Sciences Sector Is Rising
Overcoming Long-Standing Barriers
Canada’s life sciences sector has historically struggled to scale. For years, the dominance of the public health system and a reliance on foreign manufacturing kept domestic growth in check. Despite the country’s world-renowned post-secondary research institutions, translating academic output into homegrown infrastructure remained a persistent challenge.
However, recent global events have fundamentally shifted national priorities. According to Keith Reading, senior director of research at Morguard, building domestic life sciences infrastructure is now widely regarded as a strategic imperative. Canadian policymakers and industry leaders increasingly recognize that self-sufficiency in health and biotech is no longer optional.
COVID-19 Exposed Critical Infrastructure Gaps
The COVID-19 pandemic exposed a glaring weakness in Canada’s supply chain. The country lacked a domestic manufacturing base for vaccines, and that gap became a serious national concern. As a result, Canada now prioritizes building out health and biotech facilities at home rather than depending on foreign suppliers.
Moreover, Canada’s strained trade relationship with the United States amplifies this urgency. Reading noted that reliance on outside partners is no longer a sustainable position. Therefore, developing robust, homegrown capacity in the life sciences and pharmaceutical space has become a national economic priority — not just a healthcare one.
Trade Disruptions Accelerate Domestic Investment
The U.S.-Iran Conflict Adds New Pressure
The ongoing U.S.-Iran conflict introduces yet another layer of supply chain risk. Reading warned that this crisis extends well beyond oil prices. Many essential goods — including pharmaceutical raw materials and medical supplies — travel through the Strait of Hormuz. A prolonged disruption at that chokepoint will inflate global prices. Additionally, it will constrain Canada’s ability to import and export critical goods efficiently.
This context makes domestic life sciences capacity even more urgent. In short, Canada must build resilient infrastructure now to absorb future global shocks. The life sciences sector, Reading stressed, is part of a longer process of future-proofing Canada’s economy and public health system against both geopolitical and environmental disruptions.
JLL Bets Big on Canada’s Biotech Future
JLL’s investment in Canadian life sciences reflects a deliberate, global growth strategy. The firm actively targets key pharmaceutical and biotech real estate markets across multiple countries. Consequently, Seliskar’s appointment is not an isolated hire — it is part of a coordinated effort to establish JLL as the dominant player in life sciences real estate worldwide.
For Canada specifically, this development represents a vote of confidence. Industry observers see JLL’s move as a catalyst that could attract further institutional investment into Canadian life sciences real estate. As domestic pharmaceutical manufacturing gains momentum, demand for specialized facility management and real estate services will grow in tandem.
Seliskar’s arrival at JLL marks a meaningful step forward for Canada’s life sciences ecosystem — and for the global firm’s ambitions in one of real estate’s most resilient and future-facing sectors.
